Legacy Wealth Management Inc Invests $332,000 in Eli Lilly and Company (NYSE:LLY)

Legacy Wealth Management Inc acquired a new position in Eli Lilly and Company (NYSE:LLYFree Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 374 shares of the company’s stock, valued at approximately $332,000.

Several other large investors also recently added to or reduced their stakes in LLY. State of Michigan Retirement System grew its position in Eli Lilly and Company by 12.6% during the first quarter. State of Michigan Retirement System now owns 269,704 shares of the company’s stock valued at $209,819,000 after purchasing an additional 30,200 shares in the last quarter. Financial Security Advisor Inc. grew its holdings in shares of Eli Lilly and Company by 1.4% during the 1st quarter. Financial Security Advisor Inc. now owns 4,194 shares of the company’s stock valued at $3,263,000 after acquiring an additional 58 shares in the last quarter. Naviter Wealth LLC increased its stake in shares of Eli Lilly and Company by 18.3% in the first quarter. Naviter Wealth LLC now owns 4,318 shares of the company’s stock worth $3,359,000 after acquiring an additional 668 shares during the last quarter. Saxon Interests Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth $261,000. Finally, Azzad Asset Management Inc. ADV boosted its position in Eli Lilly and Company by 2.5% during the first quarter. Azzad Asset Management Inc. ADV now owns 1,814 shares of the company’s stock valued at $1,411,000 after purchasing an additional 45 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Barclays raised their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Citigroup boosted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Guggenheim raised their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,013.41.

Read Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $904.05 on Wednesday. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a market cap of $859.21 billion, a P/E ratio of 133.14, a P/E/G ratio of 3.24 and a beta of 0.42. The business’s 50 day moving average is $918.30 and its two-hundred day moving average is $865.23. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, equities analysts expect that Eli Lilly and Company will post 14.05 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.